<DOC>
	<DOCNO>NCT00541125</DOCNO>
	<brief_summary>RATIONALE : G-CSF may prevent control neutropenia cause first-line therapy patient metastatic colorectal cancer . PURPOSE : This phase II trial study well G-CSF work prevent neutropenia first-line treatment chemotherapy bevacizumab patient metastatic colorectal cancer .</brief_summary>
	<brief_title>G-CSF Preventing Neutropenia During First-Line Treatment With Chemotherapy Bevacizumab Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine primary prophylaxis comprise filgrastim ( G-CSF ) make possible obtain neutropenia low grade 4 30 % decrease fever patient metastatic colorectal cancer receive first-line FOLFIRI bevacizumab homozygous allele UGT1A1*28 ( genotype 7/7 ) , promoter gene cod enzyme UGT1A1 . Secondary - Evaluate objective response rate 6 month treatment FOLFIRI bevacizumab accord RECIST criterion . - Evaluate toxicity ( exclude neutropenia ) FOLFIRI bevacizumab accord NCI-CTC v. 2.0 . - Determine progression-free overall survival . - Determine time treatment failure . OUTLINE : This multicenter study . Patients receive bevacizumab IV 30-90 minute , irinotecan hydrochloride IV 90 minute , leucovorin calcium IV 2 hour , fluorouracil IV 46 hour day 1 . Patients also receive filgrastim ( G-CSF ) subcutaneously day 5-11 . Treatment repeat every 2 week absence disease progression unacceptable toxicity . After completion study therapy , patient follow every 2-3 month 5 year .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Inclusion criterion : Histologically confirm adenocarcinoma colon rectum Metastatic disease Not surgically curable Homozygous allele UGT1A1*28 , promoter gene cod UGT1A1 ( genotype 7/7 ) Measurable and/or evaluable disease Exclusion criterion : Original tumor remove CNS metastasis Secondary localize cerebral tumor PATIENT CHARACTERISTICS : Inclusion criterion : WHO performance status 02 ANC ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9 g/dL Creatinine &gt; 1.5 mg/dL Total bilirubin ≤ 1.5 time normal Alkaline phosphatase ≤ 2.5 time normal ( 5 time normal liver involvement ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Exclusion criterion : Progressive gastroduodenal ulcer , prior hemorrhagic ulcer , perforation past 6 month Enteropathy chronic diarrhea Chronic inflammatory intestinal disease Intestinal obstruction Active cardiac disease include follow : Uncontrolled hypertension Myocardial infarction past 12 month Serious angina NYHA class IIIV congestive heart failure Severe arrhythmia ( even treat ) Peripheral vascular disease ≥ grade 2 Unhealed wound , ulcer , severe bone fracture Bleeding disorder coagulopathy Severe uncontrolled infection medical condition Proteinuria &gt; 500 mg/24 hour Other malignancy within past 5 year except basal cell skin cancer curatively treat carcinoma situ cervix Known dihydropyrimidine dehydrogenase deficiency Severe traumatic injury within past 4 week PRIOR CONCURRENT THERAPY : Inclusion criterion : At least 2 week since prior radiotherapy Exclusion criterion : Prior chemotherapy metastatic disease except adjuvant chemotherapy complete &gt; 6 month ago Prior irinotecan hydrochloride bevacizumab Major surgery biopsy within past 4 week Major surgery plan Puncture past week Chronic aspirin ( &gt; 325 mg/day ) NSAIDs Concurrent antifungal azoles ( e.g. , ketoconazole , fluconazole , itraconazole ) Concurrent phenytoin ( yellow fever vaccine ) Concurrent Hypericum perforatum ( St. John 's wort ) Oral parenteral coagulant past 10 day study therapy Warfarin allow provide INR &lt; 1.5</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
</DOC>